dihydroxyphenylalanine has been researched along with Neuroendocrine Tumors in 55 studies
Dihydroxyphenylalanine: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.
dopa : A hydroxyphenylalanine carrying hydroxy substituents at positions 3 and 4 of the benzene ring.
Neuroendocrine Tumors: Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.
| Excerpt | Relevance | Reference |
|---|---|---|
| "(18)F-fluorodihydroxyphenylalanine (FDOPA) is a powerful tool for the diagnosis and detection of neuroendocrine tumors when planning and monitoring surgical and oncologic therapies." | 8.90 | 18F-fluorodihydroxyphenylalanine in the diagnosis of neuroendocrine tumors. ( Forsback, S; Kauhanen, S; Kemppainen, J; Minn, H; Seppänen, M, 2014) |
| "In recent years, 6-l-18F-fluorodihydroxyphenylalanine (18F-DOPA) PET has emerged as a new diagnostic tool for the imaging of neuroendocrine tumors." | 8.84 | 6-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. ( Brouwers, AH; Chirakal, R; Gulenchyn, KY; Jager, PL; Koopmans, KP; Marriott, CJ, 2008) |
| "This work was performed to evaluate the performance of (18)F-fluorodihydroxyphenylalanine ((18)F-FDOPA) PET/CT in detecting primary neuroendocrine tumors (NETs) occult on morphologic and functional imaging, in relation to tumor origin and differentiation." | 7.80 | 18F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation. ( Bachellier, P; Detour, J; Duclos, B; Gabriel, S; Goichot, B; Imperiale, A; Kurtz, JE; Namer, IJ; Rust, E; Taïeb, D, 2014) |
| "(18)F-fluorodihydroxyphenylalanine (FDOPA) is a powerful tool for the diagnosis and detection of neuroendocrine tumors when planning and monitoring surgical and oncologic therapies." | 4.90 | 18F-fluorodihydroxyphenylalanine in the diagnosis of neuroendocrine tumors. ( Forsback, S; Kauhanen, S; Kemppainen, J; Minn, H; Seppänen, M, 2014) |
| "In recent years, 6-l-18F-fluorodihydroxyphenylalanine (18F-DOPA) PET has emerged as a new diagnostic tool for the imaging of neuroendocrine tumors." | 4.84 | 6-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. ( Brouwers, AH; Chirakal, R; Gulenchyn, KY; Jager, PL; Koopmans, KP; Marriott, CJ, 2008) |
| "This work was performed to evaluate the performance of (18)F-fluorodihydroxyphenylalanine ((18)F-FDOPA) PET/CT in detecting primary neuroendocrine tumors (NETs) occult on morphologic and functional imaging, in relation to tumor origin and differentiation." | 3.80 | 18F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation. ( Bachellier, P; Detour, J; Duclos, B; Gabriel, S; Goichot, B; Imperiale, A; Kurtz, JE; Namer, IJ; Rust, E; Taïeb, D, 2014) |
| " 6-L-¹⁸F-fluorodihydroxyphenylalanine (¹⁸F-FDOPA) positron emission tomography (PET) is a relatively new metabolic imaging tracer proposed for the use of localizing sites of neuroendocrine tumors." | 3.78 | Clinical utility of functional imaging with ¹⁸F-FDOPA in Von Hippel-Lindau syndrome. ( Gesuwan, K; Herscovitch, P; Kebebew, E; Kitano, M; Linehan, WM; Millo, C; Nilubol, N; Weisbrod, AB, 2012) |
| "(68)Ga-DOTA-Tyr3-octreotide positron emission tomography ((68)Ga-DOTA-TOC PET) and (18)F-fluoro-L-dihydroxyphenylalanine PET ((18)F-DOPA PET) are emerging modalities for imaging of neuroendocrine tumors." | 3.76 | Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients. ( Gabriel, M; Henninger, B; Kendler, D; Knoflach, M; Kroiss, A; Putzer, D; Virgolini, IJ; Vonguggenberg, E; Warwitz, B, 2010) |
| "[(11)C]-5-Hydroxytryptophan ([(11)C]HTP) and 6-[(18)F]fluoro-3,4-dihydroxy-l-phenylalanine ([(18)F]FDOPA) are used to image neuroendocrine tumors with positron emission tomography." | 3.74 | Manipulation of [11C]-5-hydroxytryptophan and 6-[18F]fluoro-3,4-dihydroxy-L-phenylalanine accumulation in neuroendocrine tumor cells. ( Brouwers, AH; de Vries, EG; Dierckx, RA; Doorduin, J; Elsinga, PH; Jager, PL; Kema, IP; Koopmans, KP; Neels, OC; Timmer-Bosscha, H; van Waarde, A; Vercauteren, L, 2008) |
| "(68)Ga-DOTA-TATE PET delineated metastases in 54 of 55 positive metastatic tumour regions in contrast to 29 of 55 delineated by (18)F-DOPA PET." | 1.35 | Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. ( Auernhammer, CJ; Bartenstein, P; Göke, B; Haug, A; Pöpperl, G; Schmidt, G; Tiling, R; Wängler, B, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (20.00) | 29.6817 |
| 2010's | 36 (65.45) | 24.3611 |
| 2020's | 8 (14.55) | 2.80 |
| Authors | Studies |
|---|---|
| Morland, D | 3 |
| Jallerat, P | 1 |
| Brixi, H | 2 |
| Cadiot, G | 3 |
| Papathanassiou, D | 2 |
| Deguelte, S | 3 |
| Jallet, L | 1 |
| Lelièvre, M | 1 |
| Triumbari, EKA | 1 |
| Perrier, M | 1 |
| Jullien, M | 1 |
| Reichert, T | 1 |
| D'Anella, P | 1 |
| Castinetti, F | 1 |
| Barlier, A | 1 |
| Brue, T | 1 |
| Taieb, D | 4 |
| Cuny, T | 1 |
| Barachini, O | 1 |
| Bernt, R | 1 |
| Mirzaei, S | 1 |
| Pirich, C | 1 |
| Hergan, K | 1 |
| Zandieh, S | 1 |
| Deleval, N | 1 |
| Pesque, L | 1 |
| Dieudonné, A | 1 |
| Viry, F | 1 |
| Hentic, O | 1 |
| Lebtahi, R | 1 |
| Ruszniewski, P | 1 |
| de Mestier, L | 1 |
| Ansquer, C | 2 |
| Touchefeu, Y | 1 |
| Faivre-Chauvet, A | 1 |
| Leux, C | 1 |
| Le Bras, M | 1 |
| Régenet, N | 1 |
| Fleury, V | 1 |
| Maucherat, B | 1 |
| Senellart, H | 1 |
| Guyetant, S | 1 |
| Carlier, T | 1 |
| Scotet-Cérato, E | 1 |
| Rauscher, A | 1 |
| Frampas, E | 1 |
| Kraeber-Bodéré, F | 1 |
| Veenstra, EB | 1 |
| de Groot, DJA | 1 |
| Brouwers, AH | 6 |
| Walenkamp, AME | 3 |
| Noordzij, W | 3 |
| Cuccurullo, V | 2 |
| Prisco, MR | 1 |
| Di Stasio, GD | 2 |
| Mansi, L | 2 |
| Bozkurt, MF | 1 |
| Virgolini, I | 1 |
| Balogova, S | 2 |
| Beheshti, M | 1 |
| Rubello, D | 7 |
| Decristoforo, C | 1 |
| Ambrosini, V | 5 |
| Kjaer, A | 1 |
| Delgado-Bolton, R | 1 |
| Kunikowska, J | 1 |
| Oyen, WJG | 1 |
| Chiti, A | 2 |
| Giammarile, F | 1 |
| Sundin, A | 1 |
| Fanti, S | 7 |
| Berends, AMA | 1 |
| Kerstens, MN | 1 |
| Bolt, JW | 1 |
| Links, TP | 1 |
| Korpershoek, E | 1 |
| de Krijger, RR | 1 |
| van Etten, B | 1 |
| Kats-Ugurlu, G | 1 |
| van der Horst-Schrivers, ANA | 1 |
| Gornes, H | 1 |
| Vaysse, C | 1 |
| Deslandres, M | 1 |
| Perallon, R | 1 |
| Chantalat, E | 1 |
| Rimailho, J | 1 |
| Bergeret, S | 1 |
| Charbit, J | 1 |
| Bera, G | 1 |
| Chanson, P | 1 |
| Lussey-Lepoutre, C | 1 |
| de Hosson, LD | 1 |
| van der Loo-van der Schaaf, AM | 1 |
| Boellaard, R | 1 |
| van Snick, JH | 1 |
| de Vries, EGE | 1 |
| Talbot, JN | 1 |
| Nataf, V | 1 |
| Michaud, L | 1 |
| Huchet, V | 1 |
| Kerrou, K | 1 |
| Montravers, F | 1 |
| Imperiale, A | 7 |
| Addeo, P | 1 |
| Averous, G | 1 |
| Namer, IJ | 4 |
| Bachellier, P | 4 |
| Rust, E | 2 |
| Gabriel, S | 1 |
| Detour, J | 1 |
| Goichot, B | 2 |
| Duclos, B | 1 |
| Kurtz, JE | 1 |
| Schillaci, O | 1 |
| Minn, H | 2 |
| Kemppainen, J | 1 |
| Kauhanen, S | 2 |
| Forsback, S | 1 |
| Seppänen, M | 2 |
| Santhanam, P | 1 |
| van Beek, AP | 1 |
| Tio, RA | 1 |
| van der Horst-Schrivers, AN | 1 |
| de Vries, EG | 2 |
| van Ginkel, B | 1 |
| Walenkamp, AM | 1 |
| Glaudemans, AW | 2 |
| Slart, RH | 2 |
| Dierckx, RA | 3 |
| Kuik, WJ | 1 |
| Kema, IP | 2 |
| Zijlma, R | 1 |
| Neumann, KD | 1 |
| DiMagno, SG | 1 |
| Elsinga, PH | 2 |
| Morigi, JJ | 1 |
| Nanni, C | 6 |
| Castellucci, P | 3 |
| Garnon, J | 2 |
| Gangi, A | 2 |
| Stormezand, GN | 1 |
| Shamim, SA | 1 |
| Kumar, A | 1 |
| Kumar, R | 1 |
| Gauthé, M | 1 |
| Lièvre, A | 1 |
| Alberini, JL | 1 |
| Pacak, K | 1 |
| Cazzato, RL | 1 |
| Ramamurthy, N | 1 |
| Tsoumakidou, G | 1 |
| Caudrelier, J | 1 |
| Rao, P | 1 |
| Koch, G | 1 |
| Helali, M | 1 |
| Heimburger, C | 1 |
| Rohr, S | 1 |
| Ito, T | 1 |
| Jensen, RT | 1 |
| Trapani, A | 1 |
| Tricarico, D | 1 |
| Mele, A | 1 |
| Maqoud, F | 1 |
| Mandracchia, D | 1 |
| Vitale, P | 1 |
| Capriati, V | 1 |
| Trapani, G | 1 |
| Dimiccoli, V | 1 |
| Tolomeo, A | 1 |
| Scilimati, A | 1 |
| Arbizu, J | 1 |
| Rodriguez-Fraile, M | 1 |
| Dominguez-Prado, I | 1 |
| Garrastachu, P | 1 |
| Rotellar, F | 1 |
| Sangro, B | 1 |
| Richter, JA | 1 |
| Neels, OC | 1 |
| Koopmans, KP | 2 |
| Jager, PL | 2 |
| Vercauteren, L | 1 |
| van Waarde, A | 1 |
| Doorduin, J | 1 |
| Timmer-Bosscha, H | 1 |
| Haug, A | 1 |
| Auernhammer, CJ | 1 |
| Wängler, B | 1 |
| Tiling, R | 1 |
| Schmidt, G | 1 |
| Göke, B | 1 |
| Bartenstein, P | 1 |
| Pöpperl, G | 1 |
| Nuutila, P | 1 |
| Putzer, D | 1 |
| Gabriel, M | 1 |
| Kendler, D | 1 |
| Henninger, B | 1 |
| Knoflach, M | 1 |
| Kroiss, A | 1 |
| Vonguggenberg, E | 1 |
| Warwitz, B | 1 |
| Virgolini, IJ | 1 |
| Schiesser, M | 2 |
| Veit-Haibach, P | 2 |
| Muller, MK | 1 |
| Weber, M | 1 |
| Bauerfeind, P | 1 |
| Hany, T | 1 |
| Clavien, PA | 2 |
| Soyka, J | 1 |
| Strobel, K | 1 |
| Schaefer, NG | 1 |
| Hesselmann, R | 1 |
| Hany, TF | 1 |
| Van Binnebeek, S | 1 |
| Karges, W | 1 |
| Mottaghy, FM | 1 |
| Chondrogiannis, S | 1 |
| Grassetto, G | 1 |
| Marzola, MC | 2 |
| Rampin, L | 1 |
| Massaro, A | 1 |
| Bellan, E | 1 |
| Ferretti, A | 1 |
| Mazza, A | 1 |
| Al-Nahhas, A | 3 |
| Weisbrod, AB | 1 |
| Kitano, M | 1 |
| Gesuwan, K | 1 |
| Millo, C | 1 |
| Herscovitch, P | 1 |
| Nilubol, N | 1 |
| Linehan, WM | 1 |
| Kebebew, E | 1 |
| Lopci, E | 1 |
| Piccardo, A | 1 |
| Altrinetti, V | 1 |
| Garaventa, A | 1 |
| Pession, A | 1 |
| Cistaro, A | 1 |
| Villavecchia, G | 1 |
| Wong, KK | 1 |
| Waterfield, RT | 1 |
| Scarsbrook, AF | 1 |
| Chowdhury, FU | 1 |
| Gross, MD | 1 |
| Boulanger, C | 1 |
| Roedlich, MN | 1 |
| Ollier, JC | 1 |
| Schneegans, O | 1 |
| Sorschag, M | 1 |
| Malle, P | 1 |
| Gallowitsch, HJ | 1 |
| Treglia, G | 1 |
| Castaldi, P | 1 |
| Rufini, V | 1 |
| Becherer, A | 1 |
| Szabó, M | 1 |
| Karanikas, G | 1 |
| Wunderbaldinger, P | 1 |
| Angelberger, P | 1 |
| Raderer, M | 1 |
| Kurtaran, A | 1 |
| Dudczak, R | 1 |
| Kletter, K | 1 |
| Tomassetti, P | 2 |
| Campana, D | 2 |
| Farsad, M | 1 |
| Montini, G | 2 |
| Franchi, R | 2 |
| Seibyl, JP | 1 |
| Chen, W | 1 |
| Silverman, DH | 1 |
| Chirakal, R | 1 |
| Marriott, CJ | 1 |
| Gulenchyn, KY | 1 |
| Rizzello, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Use of Fluorodopa F 18 Positron Emission Tomography Combined With Computed Tomography in Congenital Hyperinsulinism and Insulinoma[NCT02021604] | Phase 1 | 250 participants (Anticipated) | Interventional | 2013-10-09 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 reviews available for dihydroxyphenylalanine and Neuroendocrine Tumors
| Article | Year |
|---|---|
Nuclear Medicine in Patients with NET: Radiolabeled Somatostatin Analogues and their Brothers.
Topics: Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Humans; Neuroendocrine Tumors; Nuclear Medicine; Oct | 2017 |
Physiopathological Premises to Nuclear Medicine Imaging of Pancreatic Neuroendocrine Tumours.
Topics: Animals; Dihydroxyphenylalanine; Dimerization; Edetic Acid; Fluorodeoxyglucose F18; Glucagon-Like Pe | 2019 |
Novel PET tracers: added value for endocrine disorders.
Topics: Dihydroxyphenylalanine; Endocrine System Diseases; Fluorodeoxyglucose F18; Gallium Radioisotopes; Hu | 2019 |
18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type.
Topics: 3-Iodobenzylguanidine; Bronchial Neoplasms; Carcinoma, Merkel Cell; Dihydroxyphenylalanine; Fluorode | 2013 |
18F-fluorodihydroxyphenylalanine in the diagnosis of neuroendocrine tumors.
Topics: Adrenal Gland Neoplasms; Carcinoma, Neuroendocrine; Dihydroxyphenylalanine; Humans; Intestinal Neopl | 2014 |
Role of (18) F-FDOPA PET/CT imaging in endocrinology.
Topics: Adrenal Gland Neoplasms; Carbidopa; Carcinoid Tumor; Carcinoma, Neuroendocrine; Dihydroxyphenylalani | 2014 |
Current status of PET imaging of neuroendocrine tumours ([18F]FDOPA, [68Ga]tracers, [11C]/[18F]-HTP).
Topics: 5-Hydroxytryptophan; Carbon Radioisotopes; Dihydroxyphenylalanine; Gallium Radioisotopes; Humans; Im | 2015 |
PET/Computed Tomography in Neuroendocrine Tumor: Value to Patient Management and Survival Outcomes.
Topics: Adrenal Gland Neoplasms; Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Gallium Radioisotopes; Gast | 2015 |
Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management.
Topics: Dihydroxyphenylalanine; Female; Gallium Radioisotopes; Glucagon-Like Peptide 1; Humans; Molecular Im | 2017 |
Contemporary nuclear medicine imaging of neuroendocrine tumours.
Topics: Chromaffin System; Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Ne | 2012 |
Nuclear medicine in NET.
Topics: Biomarkers, Tumor; Cell Proliferation; Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Gallium Radio | 2012 |
3,4-dihydroxy-6-[18f]-fluoro-L-phenylalanine positron emission tomography in patients with central motor disorders and in evaluation of brain and other tumors.
Topics: Adrenal Gland Neoplasms; Amino Acids; Brain Neoplasms; Caudate Nucleus; Dihydroxyphenylalanine; Fluo | 2007 |
6-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications.
Topics: Adenoma, Islet Cell; Dihydroxyphenylalanine; Humans; Hyperinsulinism; Neuroendocrine Tumors; Pancrea | 2008 |
3 trials available for dihydroxyphenylalanine and Neuroendocrine Tumors
| Article | Year |
|---|---|
18F-DOPA PET/CT in neuroblastoma: comparison of conventional imaging with CT/MR.
Topics: Child; Dihydroxyphenylalanine; Female; Humans; Magnetic Resonance Imaging; Male; Multimodal Imaging; | 2012 |
Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET.
Topics: Adult; Aged; Aged, 80 and over; Dihydroxyphenylalanine; Female; Humans; Indium Radioisotopes; Male; | 2004 |
Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours.
Topics: Adult; Aged; Aged, 80 and over; Biopsy, Needle; Digestive System Neoplasms; Dihydroxyphenylalanine; | 2007 |
39 other studies available for dihydroxyphenylalanine and Neuroendocrine Tumors
| Article | Year |
|---|---|
Performances of 18F-FDOPA PET/CT in the Preoperative Evaluation of the Peritoneal Cancer Index in Small Intestine Neuroendocrine Tumors.
Topics: Dihydroxyphenylalanine; Humans; Intestine, Small; Neuroendocrine Tumors; Positron Emission Tomograph | 2022 |
Orbital Metastasis: A Rare but Typical Location of Small Intestine Neuroendocrine Tumor on 18F-FDOPA PET/CT.
Topics: Dihydroxyphenylalanine; Humans; Intestinal Neoplasms; Intestine, Small; Neuroendocrine Tumors; Posit | 2022 |
Bone metastases in midgut neuroendocrine tumors: imaging characteristics, distribution, and risk factors.
Topics: Bone Neoplasms; Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Humans; Neuroendocrine Tumors; Posit | 2022 |
Comparison of 68Ga-Dotatate PET/CT and 18F-FDOPA PET/CT for the diagnosis of pancreatic neuroendocrine tumors in a MEN1 patient.
Topics: Dihydroxyphenylalanine; Female; Humans; Middle Aged; Multiple Endocrine Neoplasia Type 1; Neuroendoc | 2020 |
The impact of 18F-FDOPA-PET/MRI image fusion in detecting liver metastasis in patients with neuroendocrine tumors of the gastrointestinal tract.
Topics: Adult; Aged; Aged, 80 and over; Diffusion Tensor Imaging; Dihydroxyphenylalanine; Female; Gastrointe | 2020 |
Prognostic impact of bone metastases detected by
Topics: Aged; Dihydroxyphenylalanine; Humans; Neuroendocrine Tumors; Positron-Emission Tomography; Prognosis | 2021 |
Head-to-Head Comparison of 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT in Patients With Midgut Neuroendocrine Tumors.
Topics: Adult; Aged; Aged, 80 and over; Dihydroxyphenylalanine; Female; Humans; Intestinal Neoplasms; Male; | 2021 |
Comparison of 18F-DOPA Versus 68Ga-DOTATOC as Preferred PET Imaging Tracer in Well-Differentiated Neuroendocrine Neoplasms.
Topics: Adult; Dihydroxyphenylalanine; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; | 2021 |
Guideline for PET/CT imaging of neuroendocrine neoplasms with
Topics: Dihydroxyphenylalanine; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Image Interpr | 2017 |
False-positive findings on 6-[18F]fluor-l-3,4-dihydroxyphenylalanine PET (
Topics: Adrenal Gland Neoplasms; Adult; Aged; Dihydroxyphenylalanine; False Positive Reactions; Female; Huma | 2018 |
Discovery of a neuroendocrine tumor of the caecum by mammary metastasis using 18F-DOPA-PET.
Topics: Adult; Breast Neoplasms; Cecal Neoplasms; Dihydroxyphenylalanine; Female; Humans; Neoplasm Metastasi | 2018 |
Interlesional Heterogeneity of Metastatic Neuroendocrine Tumors Based on 18F-DOPA PET/CT.
Topics: Aged; Dihydroxyphenylalanine; Female; Fluorine Radioisotopes; Humans; Male; Middle Aged; Neoplasm Me | 2019 |
Solid pseudopapillary pancreatic tumor mimicking a neuroendocrine neoplasm on ¹⁸F-FDOPA PET/CT.
Topics: Adult; Carbidopa; Diagnosis, Differential; Dihydroxyphenylalanine; Dopamine Agents; Fluorine Radiois | 2013 |
18F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation.
Topics: Adult; Aged; Cohort Studies; Dihydroxyphenylalanine; Female; Humans; Male; Middle Aged; Multimodal I | 2014 |
18F-DOPA and other radiopharmaceuticals for imaging unknown primary neuroendocrine tumors.
Topics: Dihydroxyphenylalanine; Female; Humans; Male; Multimodal Imaging; Neuroendocrine Tumors; Positron-Em | 2014 |
Myocardial metastases on 6-[18F] fluoro-L-DOPA PET/CT: a retrospective analysis of 116 serotonin producing neuroendocrine tumour patients.
Topics: Carcinoid Heart Disease; Dihydroxyphenylalanine; Female; Heart Neoplasms; Humans; Male; Middle Aged; | 2014 |
In vivo biodistribution of no-carrier-added 6-18F-fluoro-3,4-dihydroxy-L-phenylalanine (18F-DOPA), produced by a new nucleophilic substitution approach, compared with carrier-added 18F-DOPA, prepared by conventional electrophilic substitution.
Topics: Animals; Cell Line, Tumor; Dihydroxyphenylalanine; Drug Stability; Humans; Male; Mice; Neuroendocrin | 2015 |
Simultaneous (18)F-FDOPA PET/CT-guided biopsy and radiofrequency ablation of recurrent neuroendocrine hepatic metastasis: further step toward a theranostic approach.
Topics: Ablation Techniques; Dihydroxyphenylalanine; Humans; Ileal Neoplasms; Image-Guided Biopsy; Liver; Li | 2015 |
(18)F-FDOPA accumulation in traumatic rib fractures: a potential pitfall.
Topics: Diagnostic Errors; Dihydroxyphenylalanine; Female; Humans; Male; Middle Aged; Multimodal Imaging; Ne | 2015 |
Primary Neuroendocrine Tumor in a Horseshoe Kidney With Positive 111In-Pentetreotide Somatostatin Receptor Scintigraphy and Negative 18F-DOPA PET/CT.
Topics: Dihydroxyphenylalanine; Female; Fused Kidney; Humans; Middle Aged; Multimodal Imaging; Neuroendocrin | 2015 |
(18)F-DOPA: the versatile radiopharmaceutical.
Topics: Biological Transport; Dihydroxyphenylalanine; Humans; Neuroendocrine Tumors; Nuclear Medicine; Radio | 2016 |
18F-FDOPA PET/CT-Guided Radiofrequency Ablation of Liver Metastases from Neuroendocrine Tumours: Technical Note on a Preliminary Experience.
Topics: Adult; Catheter Ablation; Dihydroxyphenylalanine; Female; Humans; Liver; Liver Neoplasms; Male; Midd | 2016 |
Small Bowel Carcinoid: The "Dancing Bowel Sign" on 18F-FDOPA PET/CT.
Topics: Adult; Carcinoid Tumor; Dihydroxyphenylalanine; Female; Fluorine Radioisotopes; Humans; Intestinal N | 2016 |
A novel injectable formulation of 6-fluoro-l-DOPA imaging agent for diagnosis of neuroendocrine tumors and Parkinson's disease.
Topics: Animals; beta-Cyclodextrins; Cell Line, Tumor; Chemistry, Pharmaceutical; Cysteine; Dihydroxyphenyla | 2017 |
Whole body 18fluoro-L-dopa PET-CT: a useful tool for location and surgical guidance in primary carcinoid tumours.
Topics: Adolescent; Dihydroxyphenylalanine; Female; Humans; Neuroendocrine Tumors; Positron-Emission Tomogra | 2008 |
Manipulation of [11C]-5-hydroxytryptophan and 6-[18F]fluoro-3,4-dihydroxy-L-phenylalanine accumulation in neuroendocrine tumor cells.
Topics: 5-Hydroxytryptophan; Animals; Cell Line, Tumor; Dihydroxyphenylalanine; Humans; Male; Mice; Mice, In | 2008 |
Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours.
Topics: Adult; Aged; Dihydroxyphenylalanine; Female; Gallium Radioisotopes; Humans; Male; Middle Aged; Neopl | 2009 |
18F-FDOPA: a multiple-target molecule.
Topics: Adult; Biological Transport; Dihydroxyphenylalanine; Humans; Hyperinsulinism; Infant, Newborn; Neuro | 2009 |
Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients.
Topics: Adolescent; Adult; Aged; Dihydroxyphenylalanine; Female; Gallium Radioisotopes; Humans; Male; Middle | 2010 |
Value of combined 6-[18F]fluorodihydroxyphenylalanine PET/CT for imaging of neuroendocrine tumours.
Topics: Adult; Aged; Aged, 80 and over; Dihydroxyphenylalanine; Female; Humans; Male; Middle Aged; Neuroendo | 2010 |
Clinical value of a combined multi-phase contrast enhanced DOPA-PET/CT in neuroendocrine tumours with emphasis on the diagnostic CT component.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Contrast Media; Dihydroxyphenylalanine; Female; Humans; | 2011 |
Functional imaging of neuroendocrine tumors.
Topics: 5-Hydroxytryptophan; Animals; Contrast Media; Dihydroxyphenylalanine; Dopamine; Ephedrine; Etomidate | 2011 |
18F-DOPA PET/CT biodistribution consideration in 107 consecutive patients with neuroendocrine tumours.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Dihydroxyphenylalanine; Female; Humans; Image Enh | 2012 |
Clinical utility of functional imaging with ¹⁸F-FDOPA in Von Hippel-Lindau syndrome.
Topics: Adult; Central Nervous System Neoplasms; Cohort Studies; Contrast Media; Dihydroxyphenylalanine; Fem | 2012 |
Terminal ileum neuroendocrine incidentaloma in a patient with sporadic medullary thyroid carcinoma: findings from 18F-FDOPA PET/CT investigation.
Topics: Carcinoma, Neuroendocrine; Dihydroxyphenylalanine; Female; Humans; Ileal Neoplasms; Incidental Findi | 2012 |
(18)F-DOPA PET/CT revealed synchronous neuroendocrine tumors in two sisters with MEN2A syndrome.
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Adult; Carcinoma, Medullary; Dihydroxyphenylalanine; Female; | 2013 |
18F-DOPA PET/CT and neuroendocrine tumours.
Topics: Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Humans; Neuroendocrine Tumors; Positron-Emission Tom | 2006 |
68Ga-DOTA-peptides versus 18F-DOPA PET for the assessment of NET patients.
Topics: Dihydroxyphenylalanine; Humans; Neuroendocrine Tumors; Organometallic Compounds; Positron-Emission T | 2008 |
Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours.
Topics: Aged; Aged, 80 and over; Dihydroxyphenylalanine; Female; Gastrointestinal Neoplasms; Humans; Lung Ne | 2008 |